^
Association details:
| Biomarker: | MYB fusion + PIK3CA mutation |
|---|---|
| Cancer: | Adenoid Cystic Carcinoma |
| Drug Class: | PI3K inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid
Published date:
03/01/2021
Excerpt:
Guided by the genetic alterations, the efficiencies of retinoic acid (RA) and a PI3K inhibitor were evaluated in ACC PDX models harboring both MYB fusion and PIK3CA amplification/mutation. Combination treatment of the PI3K inhibitor and RA demonstrated remarkable inhibition of tumors in PDXs harboring both PIK3CA mutation/amplification and MYB-NFIB fusion gene in vivo and in vitro.
Secondary therapy:
tretinoin
